T. Rowe Price Associates
GYRE icon

T. Rowe Price Associates’s Gyre Therapeutics GYRE Stock Holding History

T. Rowe Price Associates’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100K Buy
+15,031
New +$102K ﹤0.01% 3145
2018
Q2 		– Sell
-12,728
Closed -$2.46M – 2588
2018
Q1 		$2.46M Buy
+12,728
New +$2.37M ﹤0.01% 1525
2016
Q4 		– Sell
-219
Closed -$30K – 2557
2016
Q3 		$30K Hold
219
– – ﹤0.01% 2513
2016
Q2 		$37K Hold
219
– – ﹤0.01% 2492
2016
Q1 		$41K Buy
+219
New +$52.8K ﹤0.01% 2477

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

T. Rowe Price Associates's GYRE Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Gyre Therapeutics (GYRE) in Q2 2026: 15,031 shares worth $100K. The stake represents ﹤0.01% of the portfolio and ranks #3145 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in GYRE as recently as Q1 2018.

T. Rowe Price Associates first reported a position in GYRE in Q1 2016 and has held it in 5 quarters since. The position peaked at $2.46M in Q1 2018. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • T. Rowe Price Associates held 15,031 shares of Gyre Therapeutics worth $100K as of Q2 2026.
  • Gyre Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Gyre Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3145 holding.
  • T. Rowe Price Associates first reported a position in Gyre Therapeutics in Q1 2016 and has held it in 5 quarters since.
  • T. Rowe Price Associates's Gyre Therapeutics position peaked at $2.46M in Q1 2018.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.